GAMMA Investing LLC Purchases 822 Shares of Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC grew its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 37.8% in the first quarter, HoldingsChannel reports. The fund owned 2,994 shares of the company’s stock after acquiring an additional 822 shares during the period. GAMMA Investing LLC’s holdings in Moderna were worth $319,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of MRNA. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter worth $27,000. Arlington Trust Co LLC boosted its stake in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock worth $47,000 after buying an additional 116 shares during the last quarter. Parkside Financial Bank & Trust increased its position in shares of Moderna by 44.9% in the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares during the last quarter. Finally, Sachetta LLC bought a new stake in Moderna during the fourth quarter worth about $56,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $133.27 on Thursday. Moderna, Inc. has a one year low of $62.55 and a one year high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The firm has a market cap of $51.07 billion, a price-to-earnings ratio of -8.50 and a beta of 1.54. The stock’s fifty day moving average price is $130.56 and its two-hundred day moving average price is $109.54.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period in the prior year, the company posted $0.19 earnings per share. Moderna’s revenue was down 91.0% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Insider Activity

In other Moderna news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares in the company, valued at approximately $156,085,029.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Noubar Afeyan sold 202,832 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the sale, the director now owns 1,528,557 shares in the company, valued at approximately $226,746,145.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $105.02, for a total transaction of $1,575,300.00. Following the transaction, the president now owns 1,486,241 shares of the company’s stock, valued at $156,085,029.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,255 shares of company stock worth $55,846,531. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on MRNA shares. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Canaccord Genuity Group boosted their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Royal Bank of Canada lifted their price objective on shares of Moderna from $135.00 to $160.00 and gave the company an “outperform” rating in a research report on Monday, June 3rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $129.02.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.